Seiko DianeYamadaxGZwCqwUHe35k2lgLlPt+2z5/syyp7BaZQ==Seiko Diane Yamada41.78927490000000-87.60125000000000184Yamada, Seiko DianeOvarian CancerFallopian Tube CancerEndometrial CancerClinical Trials, RandomizedSurgeryDr. Diane Yamada specializes in the diagnosis and treatment of gynecologic cancers. She is the Section Chief for Gynecologic Oncology at the University of Chicago.
Her areas of interest include:
Surgery for gynecologic malignancies including ovarian, uterine and cervical cancers, as well as minimally invasive surgery
Prophylactic surgery for women at high risk for the development of hereditary ovarian and endometrial cancers
Management of high grade uterine cancers
Intraperitoneal chemotherapy
Novel clinical trials
Her research focuses on new treatments and drug development for ovarian and endometrial cancer, the regulation and radiologic imaging of ovarian cancer metastasis and the unique biology of aggressive uterine cancers. She conducts clinical trials targeting ovarian cancer as well as endometrial cancer.
Dr. Yamada is an editorial reviewer for a number of academic medical journals, including the American Journal of Obstetrics and Gynecology, Gynecologic Oncology, and Cancer. She is also the author or co-author of numerous peer-reviewed publications, book chapters and reviews concerning gynecologic cancers. She holds national leadership positions on the gynecologic oncology board of the American Board of Obstetrics and Gynecology and she is President-Elect II for the Society of Gynecologic Oncology.Professorplugins:FeaturedVideosFeatured Videosplugins:TwitterTwitterprns:awardConferredByaward conferred byprns:coAuthorOfcoauthor ofprns:emailEncryptedemail addressprns:endDateend dateprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:physicalNeighborOfphysical neighborprns:pluginSearchableDataProfilesRNS Plugin Searchable Dataprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:startDatestart dateprns:trainingAtOrganizationeducational organizationprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provincevivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipvivo:awardOrHonorawards and honorsAward or Honor Receiptvivo:degreeEarneddegree earnedDepartmentvivo:educationalTrainingeducation and trainingEducational Trainingvivo:freetextKeywordkeywordsvivo:hasResearchArearesearch areasvivo:hrJobTitleHR job titleInformation Resourcevivo:linkAnchorTextlink anchor textvivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:overviewoverviewvivo:personInPositionpositionsPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titleURLLinkvivo:webpagewebpagerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonAuthorship 1011214Authorship 100821827654261Feng CH, Miller CM, Tenney ME, Lee NK, Yamada SD, Hasan YInternational journal of gynecological cancer : official journal of the International Gynecological Cancer SocietyStatin Use Significantly Improves Overall Survival in High-Grade Endometrial Cancer. Int J Gynecol Cancer. 2016 11; 26(9):1642-1649.Int J Gynecol Cancer2016-11-01T00:00:002016Statin Use Significantly Improves Overall Survival in High-Grade Endometrial Cancer.28264838Chiyoda T, Hart PC, Eckert MA, McGregor SM, Lastra RR, Hamamoto R, Nakamura Y, Yamada SD, Olopade OI, Lengyel E, Romero ILCancer prevention research (Philadelphia, Pa.)Loss of BRCA1 in the Cells of Origin of Ovarian Cancer Induces Glycolysis: A Window of Opportunity for Ovarian Cancer Chemoprevention. Cancer Prev Res (Phila). 2017 Apr; 10(4):255-266.Cancer Prev Res (Phila)2017-03-06T00:00:002017Loss of BRCA1 in the Cells of Origin of Ovarian Cancer Induces Glycolysis: A Window of Opportunity for Ovarian Cancer Chemoprevention.D005185Disorders17350.967386Fallopian Tube NeoplasmsAuthorship 107329Authorship 107331Authorship 1073301Ecology and EvolutionObstetrics and Gynecology30014022Cowan M, Suntum T, Olivas AD, Perpich M, Applebaum MA, Lastra RR, Yamada SDGynecologic oncology reportsSecond primary rhabdomyosarcoma of the uterine cervix presenting with synchronous ovarian Sertoli-Leydig cell tumor: An illustrative case of DICER1 syndrome. Gynecol Oncol Rep. 2018 Aug; 25:94-97.Gynecol Oncol Rep2018-06-15T00:00:002018Second primary rhabdomyosarcoma of the uterine cervix presenting with synchronous ovarian Sertoli-Leydig cell tumor: An illustrative case of DICER1 syndrome.30241606Coscia F, Lengyel E, Duraiswamy J, Ashcroft B, Bassani-Sternberg M, Wierer M, Johnson A, Wroblewski K, Montag A, Yamada SD, López-Méndez B, Nilsson J, Mund A, Mann M, Curtis MCellMulti-level Proteomics Identifies CT45 as a Chemosensitivity Mediator and Immunotherapy Target in Ovarian Cancer. Cell. 2018 09 20; 175(1):159-170.e16.Cell2018-09-20T00:00:002018Multi-level Proteomics Identifies CT45 as a Chemosensitivity Mediator and Immunotherapy Target in Ovarian Cancer.28708786Kim JS, Mills KA, Fehniger J, Liao C, Hurteau JA, Kirschner CV, Lee NK, Rodriguez GC, Yamada SD, Diaz Moore ES, Tenney MEInternational journal of gynecological cancer : official journal of the International Gynecological Cancer SocietyVenous Thromboembolism in Patients Receiving Extended Pharmacologic Prophylaxis After Robotic Surgery for Endometrial Cancer. Int J Gynecol Cancer. 2017 10; 27(8):1774-1782.Int J Gynecol Cancer2017-10-01T00:00:002017Venous Thromboembolism in Patients Receiving Extended Pharmacologic Prophylaxis After Robotic Surgery for Endometrial Cancer.29398710Ladanyi A, Mukherjee A, Kenny HA, Johnson A, Mitra AK, Sundaresan S, Nieman KM, Pascual G, Benitah SA, Montag A, Yamada SD, Abumrad NA, Lengyel EOncogeneAdipocyte-induced CD36 expression drives ovarian cancer progression and metastasis. Oncogene. 2018 04; 37(17):2285-2301.Oncogene2018-02-05T00:00:002018Adipocyte-induced CD36 expression drives ovarian cancer progression and metastasis.30174305Curtis M, Kenny HA, Ashcroft B, Mukherjee A, Johnson A, Zhang Y, Helou Y, Batlle R, Liu X, Gutierrez N, Gao X, Yamada SD, Lastra R, Montag A, Ahsan N, Locasale JW, Salomon AR, Nebreda AR, Lengyel ECell metabolismFibroblasts Mobilize Tumor Cell Glycogen to Promote Proliferation and Metastasis. Cell Metab. 2019 01 08; 29(1):141-155.e9.Cell Metab2018-08-30T00:00:002018Fibroblasts Mobilize Tumor Cell Glycogen to Promote Proliferation and Metastasis.29656794Chapel DB, Yamada SD, Cowan M, Lastra RRGynecologic oncologyImmunohistochemistry for mismatch repair protein deficiency in endometrioid endometrial carcinoma yields equivalent results when performed on endometrial biopsy/curettage or hysterectomy specimens. Gynecol Oncol. 2018 06; 149(3):570-574.Gynecol Oncol2018-04-13T00:00:002018Immunohistochemistry for mismatch repair protein deficiency in endometrioid endometrial carcinoma yields equivalent results when performed on endometrial biopsy/curettage or hysterectomy specimens.31043742Eckert MA, Coscia F, Chryplewicz A, Chang JW, Hernandez KM, Pan S, Tienda SM, Nahotko DA, Li G, Blaženovic I, Lastra RR, Curtis M, Yamada SD, Perets R, McGregor SM, Andrade J, Fiehn O, Moellering RE, Mann M, Lengyel ENatureProteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts. Nature. 2019 05; 569(7758):723-728.Nature2019-05-01T00:00:002019Proteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts.31056111Hoppenot C, Peters P, Cowan M, Moore ED, Hurteau J, Lee NK, Yamada SDGynecologic oncologyMalignant bowel obstruction due to uterine or ovarian cancer: Are there differences in outcome? Gynecol Oncol. 2019 07; 154(1):177-182.Gynecol Oncol2019-05-02T00:00:002019Malignant bowel obstruction due to uterine or ovarian cancer: Are there differences in outcome?Authorship 196012Authorship 216584Authorship 192905Authorship 198085Authorship 243884Authorship 236662Authorship 204755Authorship 247643Authorship 213278University of California Los AngelesUniversity of California Los Angeles, MDHarbor-UCLA Medical CenterHarbor-UCLA Medical Center, InternshipHarbor-UCLA Medical CenterHarbor-UCLA Medical Center, ResidencyUniversity of California, IrvineUniversity of California, Irvine, FellowshipAmerican Board of Obstetrics and Gynecology20202014Division Board, Gynecologic OncologySociety of Gynecologic Oncology20222021President Authorship 1306817Authorship 13068212Authorship 13068310Authorship 13068412Authorship 1306857Authorship 1306862Authorship 13068711Authorship 1306888Authorship 13068913Authorship 1306906Authorship 1306917Authorship 1306928Authorship 1306937Authorship 1306947Authorship 1306957Authorship 1306965Authorship 130697721277623Morgan MA, Sill MW, Fujiwara K, Greer B, Rubin SC, Degeest K, Yamada SD, Waggoner S, Coleman RL, Walker JL, Mannel RSGynecologic oncologyA phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol. 2011 May 01; 121(2):264-8.Gynecol Oncol2011-02-01T00:00:002011A phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A Gynecologic Oncology Group study.24166194Brown J, Brady WE, Schink J, Van Le L, Leitao M, Yamada SD, de Geest K, Gershenson DMCancerEfficacy and safety of bevacizumab in recurrent sex cord-stromal ovarian tumors: results of a phase 2 trial of the Gynecologic Oncology Group. Cancer. 2014 Feb 01; 120(3):344-51.Cancer2013-10-24T00:00:002013Efficacy and safety of bevacizumab in recurrent sex cord-stromal ovarian tumors: results of a phase 2 trial of the Gynecologic Oncology Group.23262204Alvarez EA, Brady WE, Walker JL, Rotmensch J, Zhou XC, Kendrick JE, Yamada SD, Schilder JM, Cohn DE, Harrison CR, Moore KN, Aghajanian CGynecologic oncologyPhase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2013 Apr; 129(1):22-7.Gynecol Oncol2012-12-20T00:00:002012Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study.23261356Farley J, Brady WE, Vathipadiekal V, Lankes HA, Coleman R, Morgan MA, Mannel R, Yamada SD, Mutch D, Rodgers WH, Birrer M, Gershenson DMThe Lancet. OncologySelumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol. 2013 Feb; 14(2):134-40.Lancet Oncol2012-12-21T00:00:002012Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study.22943879Gould N, Sill MW, Mannel RS, Thaker PH, DiSilvestro PA, Waggoner SE, Yamada SD, Armstrong DK, Fracasso PM, Walker JLGynecologic oncologyA phase I study with an expanded cohort to assess feasibility of intravenous docetaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with previously untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 Dec; 127(3):506-10.Gynecol Oncol2012-08-31T00:00:002012A phase I study with an expanded cohort to assess feasibility of intravenous docetaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with previously untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.22192729Gotlieb WH, Amant F, Advani S, Goswami C, Hirte H, Provencher D, Somani N, Yamada SD, Tamby JF, Vergote IThe Lancet. OncologyIntravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol. 2012 Feb; 13(2):154-62.Lancet Oncol2011-12-20T00:00:002011Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study.22155262Gould N, Sill MW, Mannel RS, Thaker PH, Disilvestro P, Waggoner S, Yamada SD, Armstrong DK, Wenzel L, Huang H, Fracasso PM, Walker JLGynecologic oncologyA phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 Apr; 125(1):54-8.Gynecol Oncol2011-12-11T00:00:002011A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.21820161Dizon DS, Sill MW, Gould N, Rubin SC, Yamada SD, Debernardo RL, Mannel RS, Eisenhauer EL, Duska LR, Fracasso PMGynecologic oncologyPhase I feasibility study of intraperitoneal cisplatin and intravenous paclitaxel followed by intraperitoneal paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: a gynecologic oncology group study. Gynecol Oncol. 2011 Nov; 123(2):182-6.Gynecol Oncol2011-08-05T00:00:002011Phase I feasibility study of intraperitoneal cisplatin and intravenous paclitaxel followed by intraperitoneal paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: a gynecologic oncology group study.Authorship 232023Authorship 266527Authorship 192885Authorship 193784Authorship 289676Authorship 223253Authorship 315189D010051Disorders1667380.613506Ovarian NeoplasmsAuthorship 330857Authorship 252733Authorship 353676Authorship 281253Authorship 297766Authorship 353123Authorship 379372Authorship 434323Authorship 306956Authorship 3468913Authorship 392415Authorship 322563Authorship 393767D014594Disorders602250.739689Uterine NeoplasmsAuthorship 136198532190321Kondo T, Tasaka T, Shimizu R, Hayashi K, Yamada S, Fukuda H, Hirose T, Takeuchi A, Sano F, Tokunaga H, Matsuhashi Y, Wada HMolecular and clinical oncologyJumping translocations of 1q in donor cell-derived myelodysplastic syndrome after cord blood transplantation: Case report and review of the literature. Mol Clin Oncol. 2020 Apr; 12(4):365-373.Mol Clin Oncol2020-02-06T00:00:002020Jumping translocations of 1q in donor cell-derived myelodysplastic syndrome after cord blood transplantation: Case report and review of the literature.Authorship 433494Authorship 448587Authorship 471086Authorship 476753Authorship 491008AymanAl-HendyAyman Al-Hendy41.7886000000000087.598699999999993954Al-Hendy, AymanProfessorAuthorship 1290816Authorship 215801Authorship 254366Authorship 346858Authorship 4519198945470Yamagata K, Oda N, Kaisaki PJ, Menzel S, Furuta H, Vaxillaire M, Southam L, Cox RD, Lathrop GM, Boriraj VV, Chen X, Cox NJ, Oda Y, Yano H, Le Beau MM, Yamada S, Nishigori H, Takeda J, Fajans SS, Hattersley AT, Iwasaki N, Hansen T, Pedersen O, Polonsky KS, Bell GINatureMutations in the hepatocyte nuclear factor-1alpha gene in maturity-onset diabetes of the young (MODY3) Nature. 1996 Dec 05; 384(6608):455-8.Nature1996-12-05T00:00:001996Mutations in the hepatocyte nuclear factor-1alpha gene in maturity-onset diabetes of the young (MODY3)11606109Adams SF, Yamada SD, Montag A, Rotmensch JRGynecologic oncologyAn alpha-fetoprotein-producing hepatoid adenocarcinoma of the endometrium. Gynecol Oncol. 2001 Nov; 83(2):418-21.Gynecol Oncol2001-11-01T00:00:002001An alpha-fetoprotein-producing hepatoid adenocarcinoma of the endometrium.11733964Phelan C, Montag AG, Rotmensch J, Waggoner SE, Yamada SD, Mundt AJGynecologic oncologyOutcome and management of pathological stage I endometrial carcinoma patients with involvement of the lower uterine segment. Gynecol Oncol. 2001 Dec; 83(3):513-7.Gynecol Oncol2001-12-01T00:00:002001Outcome and management of pathological stage I endometrial carcinoma patients with involvement of the lower uterine segment.12236055Garber ED, Ruddat MAdvances in applied microbiologyTransmission genetics of Microbotryum violaceum (Ustilago violacea): a case history. Adv Appl Microbiol. 2002; 51:107-27.Adv Appl Microbiol2002-01-01T00:00:002002Transmission genetics of Microbotryum violaceum (Ustilago violacea): a case history.12359053Tsuchida R, Miyauchi J, Shen L, Takagi M, Tsunematsu Y, Saeki M, Honna T, Yamada S, Teraoka H, Kato JY, Mizutani SJapanese journal of cancer research : GannExpression of cyclin-dependent kinase inhibitor p27/Kip1 and AP-1 coactivator p38/Jab1 correlates with differentiation of embryonal rhabdomyosarcoma. Jpn J Cancer Res. 2002 Sep; 93(9):1000-6.Jpn J Cancer Res2002-09-01T00:00:002002Expression of cyclin-dependent kinase inhibitor p27/Kip1 and AP-1 coactivator p38/Jab1 correlates with differentiation of embryonal rhabdomyosarcoma.11520140Mundt AJ, Roeske JC, Lujan AE, Yamada SD, Waggoner SE, Fleming G, Rotmensch JGynecologic oncologyInitial clinical experience with intensity-modulated whole-pelvis radiation therapy in women with gynecologic malignancies. Gynecol Oncol. 2001 Sep; 82(3):456-63.Gynecol Oncol2001-09-01T00:00:002001Initial clinical experience with intensity-modulated whole-pelvis radiation therapy in women with gynecologic malignancies.11955746Mundt AJ, Lujan AE, Rotmensch J, Waggoner SE, Yamada SD, Fleming G, Roeske JCInternational journal of radiation oncology, biology, physicsIntensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies. Int J Radiat Oncol Biol Phys. 2002 Apr 01; 52(5):1330-7.Int J Radiat Oncol Biol Phys2002-04-01T00:00:002002Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies.12459361Brixey CJ, Roeske JC, Lujan AE, Yamada SD, Rotmensch J, Mundt AJInternational journal of radiation oncology, biology, physicsImpact of intensity-modulated radiotherapy on acute hematologic toxicity in women with gynecologic malignancies. Int J Radiat Oncol Biol Phys. 2002 Dec 01; 54(5):1388-96.Int J Radiat Oncol Biol Phys2002-12-01T00:00:002002Impact of intensity-modulated radiotherapy on acute hematologic toxicity in women with gynecologic malignancies.12438272Yamada SD, Hickson JA, Hrobowski Y, Vander Griend DJ, Benson D, Montag A, Karrison T, Huo D, Rutgers J, Adams S, Rinker-Schaeffer CWCancer researchMitogen-activated protein kinase kinase 4 (MKK4) acts as a metastasis suppressor gene in human ovarian carcinoma. Cancer Res. 2002 Nov 15; 62(22):6717-23.Cancer Res2002-11-15T00:00:002002Mitogen-activated protein kinase kinase 4 (MKK4) acts as a metastasis suppressor gene in human ovarian carcinoma.15121630Rana S, Warren BK, Yamada SDObstetrics and gynecologyStage IIIC small cell carcinoma of the ovary: survival with conservative surgery and chemotherapy. Obstet Gynecol. 2004 May; 103(5 Pt 2):1120-3.Obstet Gynecol2004-05-01T00:00:002004Stage IIIC small cell carcinoma of the ovary: survival with conservative surgery and chemotherapy.15328195Mell LK, Meyer JJ, Tretiakova M, Khramtsov A, Gong C, Yamada SD, Montag AG, Mundt AJClinical cancer research : an official journal of the American Association for Cancer ResearchPrognostic significance of E-cadherin protein expression in pathological stage I-III endometrial cancer. Clin Cancer Res. 2004 Aug 15; 10(16):5546-53.Clin Cancer Res2004-08-15T00:00:002004Prognostic significance of E-cadherin protein expression in pathological stage I-III endometrial cancer.15752887Schroder M, Mell LK, Hurteau JA, Collins YC, Rotmensch J, Waggoner SE, Yamada SD, Small W, Mundt AJInternational journal of radiation oncology, biology, physicsClitoral therapy device for treatment of sexual dysfunction in irradiated cervical cancer patients. Int J Radiat Oncol Biol Phys. 2005 Mar 15; 61(4):1078-86.Int J Radiat Oncol Biol Phys2005-03-15T00:00:002005Clitoral therapy device for treatment of sexual dysfunction in irradiated cervical cancer patients.15896989Birch LE, Ruddat MFungal genetics and biology : FG & BSiderophore accumulation and phytopathogenicity in Microbotryum violaceum. Fungal Genet Biol. 2005 Jul; 42(7):579-89.Fungal Genet Biol2005-07-01T00:00:002005Siderophore accumulation and phytopathogenicity in Microbotryum violaceum.14575831Mehta N, Yamada SD, Rotmensch J, Mundt AJInternational journal of radiation oncology, biology, physicsOutcome and pattern of failure in pathologic stage I-II papillary serous carcinoma of the endometrium: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys. 2003 Nov 15; 57(4):1004-9.Int J Radiat Oncol Biol Phys2003-11-15T00:00:002003Outcome and pattern of failure in pathologic stage I-II papillary serous carcinoma of the endometrium: implications for adjuvant radiation therapy.16226796Dewdney S, Sokoloff M, Yamada SDGynecologic oncologyConservative management of chylous ascites after removal of a symptomatic growing retroperitoneal teratoma. Gynecol Oncol. 2006 Mar; 100(3):608-11.Gynecol Oncol2005-10-14T00:00:002005Conservative management of chylous ascites after removal of a symptomatic growing retroperitoneal teratoma.16757127Mell LK, Kochanski JD, Roeske JC, Haslam JJ, Mehta N, Yamada SD, Hurteau JA, Collins YC, Lengyel E, Mundt AJInternational journal of radiation oncology, biology, physicsDosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy. Int J Radiat Oncol Biol Phys. 2006 Dec 01; 66(5):1356-65.Int J Radiat Oncol Biol Phys2006-06-06T00:00:002006Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy.Medicine-Hematology and OncologyObstetrics and Gynecology-GeneralistsObstetrics and Gynecology-Gynecologic Oncology17049587Adams SF, Hickson JA, Hutto JY, Montag AG, Lengyel E, Yamada SDGynecologic oncologyPDGFR-alpha as a potential therapeutic target in uterine sarcomas. Gynecol Oncol. 2007 Mar; 104(3):524-8.Gynecol Oncol2006-10-17T00:00:002006PDGFR-alpha as a potential therapeutic target in uterine sarcomas.14984944Mundt AJ, Rotmensch J, Waggoner SE, Yamada SD, Fleming GFGynecologic oncologyPhase I trial of concomitant vinorelbine, cisplatin, and pelvic irradiation in cervical carcinoma and other advanced pelvic malignancies. Gynecol Oncol. 2004 Mar; 92(3):801-5.Gynecol Oncol2004-03-01T00:00:002004Phase I trial of concomitant vinorelbine, cisplatin, and pelvic irradiation in cervical carcinoma and other advanced pelvic malignancies.16489030Hickson JA, Huo D, Vander Griend DJ, Lin A, Rinker-Schaeffer CW, Yamada SDCancer researchThe p38 kinases MKK4 and MKK6 suppress metastatic colonization in human ovarian carcinoma. Cancer Res. 2006 Feb 15; 66(4):2264-70.Cancer Res2006-02-15T00:00:002006The p38 kinases MKK4 and MKK6 suppress metastatic colonization in human ovarian carcinoma.12957265Lujan AE, Mundt AJ, Yamada SD, Rotmensch J, Roeske JCInternational journal of radiation oncology, biology, physicsIntensity-modulated radiotherapy as a means of reducing dose to bone marrow in gynecologic patients receiving whole pelvic radiotherapy. Int J Radiat Oncol Biol Phys. 2003 Oct 01; 57(2):516-21.Int J Radiat Oncol Biol Phys2003-10-01T00:00:002003Intensity-modulated radiotherapy as a means of reducing dose to bone marrow in gynecologic patients receiving whole pelvic radiotherapy.17889676Lotan TL, Tefs K, Schuster V, Miller J, Manaligod J, Filstead A, Yamada SD, Krausz THuman pathologyInherited plasminogen deficiency presenting as ligneous vaginitis: a case report with molecular correlation and review of the literature. Hum Pathol. 2007 Oct; 38(10):1569-75.Hum Pathol2007-10-01T00:00:002007Inherited plasminogen deficiency presenting as ligneous vaginitis: a case report with molecular correlation and review of the literature.18381422Lotan T, Hickson J, Souris J, Huo D, Taylor J, Li T, Otto K, Yamada SD, Macleod K, Rinker-Schaeffer CWCancer researchc-Jun NH2-terminal kinase activating kinase 1/mitogen-activated protein kinase kinase 4-mediated inhibition of SKOV3ip.1 ovarian cancer metastasis involves growth arrest and p21 up-regulation. Cancer Res. 2008 Apr 01; 68(7):2166-75.Cancer Res2008-04-01T00:00:002008c-Jun NH2-terminal kinase activating kinase 1/mitogen-activated protein kinase kinase 4-mediated inhibition of SKOV3ip.1 ovarian cancer metastasis involves growth arrest and p21 up-regulation.18554701Onujiogu N, Lengyel E, Yamada SDGynecologic oncologyReversible posterior leukoencephalopathy syndrome following intravenous paclitaxel and intraperitoneal cisplatin chemotherapy for fallopian tube cancer. Gynecol Oncol. 2008 Dec; 111(3):537-9.Gynecol Oncol2008-06-13T00:00:002008Reversible posterior leukoencephalopathy syndrome following intravenous paclitaxel and intraperitoneal cisplatin chemotherapy for fallopian tube cancer.18572308Taylor JL, Szmulewitz RZ, Lotan T, Hickson J, Griend DV, Yamada SD, Macleod K, Rinker-Schaeffer CWCancer lettersNew paradigms for the function of JNKK1/MKK4 in controlling growth of disseminated cancer cells. Cancer Lett. 2008 Dec 08; 272(1):12-22.Cancer Lett2008-06-24T00:00:002008New paradigms for the function of JNKK1/MKK4 in controlling growth of disseminated cancer cells.19383827Melhem A, Yamada SD, Fleming GF, Delgado B, Brickley DR, Wu W, Kocherginsky M, Conzen SDClinical cancer research : an official journal of the American Association for Cancer ResearchAdministration of glucocorticoids to ovarian cancer patients is associated with expression of the anti-apoptotic genes SGK1 and MKP1/DUSP1 in ovarian tissues. Clin Cancer Res. 2009 May 01; 15(9):3196-204.Clin Cancer Res2009-04-21T00:00:002009Administration of glucocorticoids to ovarian cancer patients is associated with expression of the anti-apoptotic genes SGK1 and MKP1/DUSP1 in ovarian tissues.17308108Sawada K, Radjabi AR, Shinomiya N, Kistner E, Kenny H, Becker AR, Turkyilmaz MA, Salgia R, Yamada SD, Vande Woude GF, Tretiakova MS, Lengyel ECancer researchc-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res. 2007 Feb 15; 67(4):1670-9.Cancer Res2007-02-15T00:00:002007c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion.18381440Sawada K, Mitra AK, Radjabi AR, Bhaskar V, Kistner EO, Tretiakova M, Jagadeeswaran S, Montag A, Becker A, Kenny HA, Peter ME, Ramakrishnan V, Yamada SD, Lengyel ECancer researchLoss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target. Cancer Res. 2008 Apr 01; 68(7):2329-39.Cancer Res2008-04-01T00:00:002008Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target.D016889Disorders641910.802339Endometrial Neoplasms21551255Zillhardt M, Park SM, Romero IL, Sawada K, Montag A, Krausz T, Yamada SD, Peter ME, Lengyel EClinical cancer research : an official journal of the American Association for Cancer ResearchForetinib (GSK1363089), an orally available multikinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian cancer metastasis. Clin Cancer Res. 2011 Jun 15; 17(12):4042-51.Clin Cancer Res2011-05-06T00:00:002011Foretinib (GSK1363089), an orally available multikinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian cancer metastasis.22350525Bainer RO, Veneris JT, Yamada SD, Montag A, Lingen MW, Gilad Y, Rinker-Schaeffer CWClinical & experimental metastasisTime-dependent transcriptional profiling links gene expression to mitogen-activated protein kinase kinase 4 (MKK4)-mediated suppression of omental metastatic colonization. Clin Exp Metastasis. 2012 Jun; 29(5):397-408.Clin Exp Metastasis2012-02-21T00:00:002012Time-dependent transcriptional profiling links gene expression to mitogen-activated protein kinase kinase 4 (MKK4)-mediated suppression of omental metastatic colonization.22037646Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt MR, Romero IL, Carey MS, Mills GB, Hotamisligil GS, Yamada SD, Peter ME, Gwin K, Lengyel ENature medicineAdipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med. 2011 Oct 30; 17(11):1498-503.Nat Med2011-10-30T00:00:002011Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth.19808644Kaur S, Kenny HA, Jagadeeswaran S, Zillhardt MR, Montag AG, Kistner E, Yamada SD, Mitra AK, Lengyel EThe American journal of pathology{beta}3-integrin expression on tumor cells inhibits tumor progression, reduces metastasis, and is associated with a favorable prognosis in patients with ovarian cancer. Am J Pathol. 2009 Nov; 175(5):2184-96.Am J Pathol2009-10-01T00:00:002009{beta}3-integrin expression on tumor cells inhibits tumor progression, reduces metastasis, and is associated with a favorable prognosis in patients with ovarian cancer.21149615Kenny HA, Leonhardt P, Ladanyi A, Yamada SD, Montag A, Im HK, Jagadeeswaran S, Shaw DE, Mazar AP, Lengyel EClinical cancer research : an official journal of the American Association for Cancer ResearchTargeting the urokinase plasminogen activator receptor inhibits ovarian cancer metastasis. Clin Cancer Res. 2011 Feb 01; 17(3):459-71.Clin Cancer Res2010-12-13T00:00:002010Targeting the urokinase plasminogen activator receptor inhibits ovarian cancer metastasis.16657007Ruddat MPlant physiologyGibberellin-like Substances From Vegetative Tissue of a Conifer, Arizona Cypress. Plant Physiol. 1968 Dec; 43(12):2049-53.Plant Physiol1968-12-01T00:00:001968Gibberellin-like Substances From Vegetative Tissue of a Conifer, Arizona Cypress.22835717Tergas AI, Buell-Gutbrod R, Gwin K, Kocherginsky M, Temkin SM, Fefferman A, Lengyel E, Yamada SDGynecologic oncologyClinico-pathologic comparison of type II endometrial cancers based on tamoxifen exposure. Gynecol Oncol. 2012 Nov; 127(2):316-20.Gynecol Oncol2012-07-24T00:00:002012Clinico-pathologic comparison of type II endometrial cancers based on tamoxifen exposure.21656742Hill EK, Sandbo S, Abramsohn E, Makelarski J, Wroblewski K, Wenrich ER, McCoy S, Temkin SM, Yamada SD, Lindau STCancerAssessing gynecologic and breast cancer survivors' sexual health care needs. Cancer. 2011 Jun 15; 117(12):2643-51.Cancer2010-12-23T00:00:002010Assessing gynecologic and breast cancer survivors' sexual health care needs.17546601Kenny HA, Krausz T, Yamada SD, Lengyel EInternational journal of cancerUse of a novel 3D culture model to elucidate the role of mesothelial cells, fibroblasts and extra-cellular matrices on adhesion and invasion of ovarian cancer cells to the omentum. Int J Cancer. 2007 Oct 01; 121(7):1463-72.Int J Cancer2007-10-01T00:00:002007Use of a novel 3D culture model to elucidate the role of mesothelial cells, fibroblasts and extra-cellular matrices on adhesion and invasion of ovarian cancer cells to the omentum.21168200Bishop EA, Lengyel ER, Yamada SD, Montag A, Temkin SMGynecologic oncologyThe expression of hepatocyte growth factor (HGF) and c-Met in uterine serous carcinoma. Gynecol Oncol. 2011 Apr; 121(1):218-23.Gynecol Oncol2010-12-17T00:00:002010The expression of hepatocyte growth factor (HGF) and c-Met in uterine serous carcinoma.11483323Mundt AJ, McBride R, Rotmensch J, Waggoner SE, Yamada SD, Connell PPInternational journal of radiation oncology, biology, physicsSignificant pelvic recurrence in high-risk pathologic stage I--IV endometrial carcinoma patients after adjuvant chemotherapy alone: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys. 2001 Aug 01; 50(5):1145-53.Int J Radiat Oncol Biol Phys2001-08-01T00:00:002001Significant pelvic recurrence in high-risk pathologic stage I--IV endometrial carcinoma patients after adjuvant chemotherapy alone: implications for adjuvant radiation therapy.11483324Mundt AJ, Murphy KT, Rotmensch J, Waggoner SE, Yamada SD, Connell PPInternational journal of radiation oncology, biology, physicsSurgery and postoperative radiation therapy in FIGO Stage IIIC endometrial carcinoma. Int J Radiat Oncol Biol Phys. 2001 Aug 01; 50(5):1154-60.Int J Radiat Oncol Biol Phys2001-08-01T00:00:002001Surgery and postoperative radiation therapy in FIGO Stage IIIC endometrial carcinoma.12654437Murphy KT, Rotmensch J, Yamada SD, Mundt AJInternational journal of radiation oncology, biology, physicsOutcome and patterns of failure in pathologic stages I-IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys. 2003 Apr 01; 55(5):1272-6.Int J Radiat Oncol Biol Phys2003-04-01T00:00:002003Outcome and patterns of failure in pathologic stages I-IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy.15275729Citron JR, Sutton H, Yamada SD, Mehta N, Mundt AJInternational journal of radiation oncology, biology, physicsPathologic stage I-II endometrial carcinoma in the elderly: radiotherapy indications and outcome. Int J Radiat Oncol Biol Phys. 2004 Aug 01; 59(5):1432-8.Int J Radiat Oncol Biol Phys2004-08-01T00:00:002004Pathologic stage I-II endometrial carcinoma in the elderly: radiotherapy indications and outcome.19763444Kenny HA, Dogan S, Zillhardt M, K Mitra A, Yamada SD, Krausz T, Lengyel ECancer treatment and researchOrganotypic models of metastasis: A three-dimensional culture mimicking the human peritoneum and omentum for the study of the early steps of ovarian cancer metastasis. Cancer Treat Res. 2009; 149:335-51.Cancer Treat Res2009-01-01T00:00:002009Organotypic models of metastasis: A three-dimensional culture mimicking the human peritoneum and omentum for the study of the early steps of ovarian cancer metastasis.D010534Disorders721750.873349Peritoneal Neoplasms22183212Romero IL, McCormick A, McEwen KA, Park S, Karrison T, Yamada SD, Pannain S, Lengyel EObstetrics and gynecologyRelationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity. Obstet Gynecol. 2012 Jan; 119(1):61-7.Obstet Gynecol2012-01-01T00:00:002012Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity.25202979Kenny HA, Chiang CY, White EA, Schryver EM, Habis M, Romero IL, Ladanyi A, Penicka CV, George J, Matlin K, Montag A, Wroblewski K, Yamada SD, Mazar AP, Bowtell D, Lengyel EThe Journal of clinical investigationMesothelial cells promote early ovarian cancer metastasis through fibronectin secretion. J Clin Invest. 2014 Oct; 124(10):4614-28.J Clin Invest2014-09-09T00:00:002014Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion.25118694Habis M, Wroblewski K, Bradaric M, Ismail N, Yamada SD, Litchfield L, Lengyel E, Romero ILPloS oneStatin therapy is associated with improved survival in patients with non-serous-papillary epithelial ovarian cancer: a retrospective cohort analysis. PLoS One. 2014; 9(8):e104521.PLoS One2014-08-13T00:00:002014Statin therapy is associated with improved survival in patients with non-serous-papillary epithelial ovarian cancer: a retrospective cohort analysis.Authorship 158341635985004Hlubocky FJ, Daugherty CK, Peppercorn J, Young K, Wroblewski KE, Yamada SD, Lee NKJCO clinical cancer informaticsUtilization of an Electronic Patient-Reported Outcome Platform to Evaluate the Psychosocial and Quality-of-Life Experience Among a Community Sample of Ovarian Cancer Survivors. JCO Clin Cancer Inform. 2022 08; 6:e2200035.JCO Clin Cancer Inform2022-08-01T00:00:002022Utilization of an Electronic Patient-Reported Outcome Platform to Evaluate the Psychosocial and Quality-of-Life Experience Among a Community Sample of Ovarian Cancer Survivors.https://cgh.uchicago.edu/page/leadershipGlobal Healthhttps://obgyn.uchicago.edu/page/section-gynecologic-oncologyGynecologic Oncology Section - Univ. of Chicagohttps://www.uchicagomedicine.org/find-a-physician/physician/olufunmilayo-i-olopadeUChicago Medicinehttps://obgyn.uchicago.edu/Univ. of Chicago OB&GYNhttp://obg.bsd.uchicago.edu/FacultyResearch/lengyellab.htmOvarian Cancer Laboratory in Chicagohttps://voices.uchicago.edu/trevorpricelab/Price Lab websitehttps://cancerbio.uchicago.edu/program/faculty/olufunmilayo-olopadeCancer Biologyhttps://www.uchicagomedicine.org/conditions-services/cancer/cancer-risk-preventionCancer Risk and Preventionhttps://www.uchicagomedicine.org/find-a-physician/physician/ernst-lengyelClinical Profilehttps://womanlab.org/WomanLabhttps://www.uchicagomedicine.org/conditions-services/obgyn/specialtyOB&GYN Clinical Patient information@WomanLab_MedicinePathologyUniversity of ChicagoGiniFleming0GRlDqwcF+v5hHlsaUXv9Gq0+s+oGini Fleming41.78927490000000-87.601250000000001804Fleming, GiniProfessor2.925790.00472312380research areas1.984670.0094138147coauthor of74.77437.3253760similar to1176selected publicationsErnst RobertLengyel0m5sBaYMHOD5hHlsaUXv9Gq0+s+oErnst Robert Lengyel41.78927490000000-87.601250000000001942Lengyel, Ernst RobertProfessorIrisRomeroIris Romero41.78927490000000-87.601250000000001946Romero, IrisProfessorOlufunmilayoOlopade321vBIF1GuTQkntjbwjr93A=Olufunmilayo Olopade41.78927490000000-87.601250000000001960Olopade, OlufunmilayoProfessorCarrie W.Rinker-SchaefferCarrie W. Rinker-Schaeffer41.78927490000000-87.601250000000002220Rinker-Schaeffer, Carrie W.ProfessorTrevor D.PriceTrevor D. Price41.78927490000000-87.601250000000002239Price, Trevor D.ProfessorStacyLindauStacy Lindau41.78927490000000-87.601250000000002240Lindau, StacyProfessorHilaryKennyHilary Kenny41.78927490000000-87.601250000000002548Kenny, HilaryResearch Associate ProfessorYusukeNakamuraYusuke Nakamura41.78927490000000-87.60125000000000582Nakamura, YusukeEmeritus/Emerita, ProfessorShirley RBaronShirley R Baron41.78927490000000-87.60125000000000789Baron, Shirley RClinical AssociateNitaLeeNita Lee41.78927490000000-87.6012500000000095Lee, NitaAssociate Professortrue1ProfessorProfessortrue1Emeritus/Emerita, ProfessorEmeritus/Emerita, Professortrue1ProfessorProfessortrue1ProfessorProfessortrue1Research Associate ProfessorResearch Associate Professortrue1ProfessorProfessortrue1ProfessorProfessortrue1Associate ProfessorAssociate Professortrue1ProfessorProfessortrue1Clinical AssociateClinical Associatetrue1ProfessorProfessortrue1ProfessorProfessortrue1Associate ProfessorAssociate Professortrue1ProfessorProfessorAuthorship 667685Authorship 7417515Authorship 77888825199754Sherman ME, Piedmonte M, Mai PL, Ioffe OB, Ronnett BM, Van Le L, Ivanov I, Bell MC, Blank SV, DiSilvestro P, Hamilton CA, Tewari KS, Wakeley K, Kauff ND, Yamada SD, Rodriguez G, Skates SJ, Alberts DS, Walker JL, Minasian L, Lu K, Greene MHJournal of clinical oncology : official journal of the American Society of Clinical OncologyPathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199. J Clin Oncol. 2014 Oct 10; 32(29):3275-83.J Clin Oncol2014-09-08T00:00:002014Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199.25582823Kennedy V, Abramsohn E, Makelarski J, Barber R, Wroblewski K, Tenney M, Lee NK, Yamada SD, Lindau STGynecologic oncologyCan you ask? We just did! Assessing sexual function and concerns in patients presenting for initial gynecologic oncology consultation. Gynecol Oncol. 2015 Apr; 137(1):119-24.Gynecol Oncol2015-01-09T00:00:002015Can you ask? We just did! Assessing sexual function and concerns in patients presenting for initial gynecologic oncology consultation.Authorship 795841225838164Hunn J, Tenney ME, Tergas AI, Bishop EA, Moore K, Watkin W, Kirschner C, Hurteau J, Rodriguez GC, Lengyel E, Lee NK, Yamada SDGynecologic oncologyPatterns and utility of routine surveillance in high grade endometrial cancer. Gynecol Oncol. 2015 Jun; 137(3):485-9.Gynecol Oncol2015-03-30T00:00:002015Patterns and utility of routine surveillance in high grade endometrial cancer.Authorship 80411526137577He C, Chan C, Weichselbaum RR, Fleming GF, Yamada SD, Lin WEBioMedicineNanomedicine for Combination Therapy of Cancer. EBioMedicine. 2015 May; 2(5):366-7.EBioMedicine2015-05-13T00:00:002015Nanomedicine for Combination Therapy of Cancer.Surgery-UrologyRicardoLastraRicardo Lastra0.000000000000000.000000000000003226Lastra, RicardoAssociate ProfessorChicago60637ILAuthorship 89675427088560He C, Poon C, Chan C, Yamada SD, Lin WJournal of the American Chemical SocietyNanoscale Coordination Polymers Codeliver Chemotherapeutics and siRNAs to Eradicate Tumors of Cisplatin-Resistant Ovarian Cancer. J Am Chem Soc. 2016 05 11; 138(18):6010-9.J Am Chem Soc2016-05-02T00:00:002016Nanoscale Coordination Polymers Codeliver Chemotherapeutics and siRNAs to Eradicate Tumors of Cisplatin-Resistant Ovarian Cancer.Authorship 91132727103176Fehniger J, Thomas S, Lengyel E, Liao C, Tenney M, Oto A, Yamada SDGynecologic oncologyA prospective study evaluating diffusion weighted magnetic resonance imaging (DW-MRI) in the detection of peritoneal carcinomatosis in suspected gynecologic malignancies. Gynecol Oncol. 2016 07; 142(1):169-175.Gynecol Oncol2016-04-28T00:00:002016A prospective study evaluating diffusion weighted magnetic resonance imaging (DW-MRI) in the detection of peritoneal carcinomatosis in suspected gynecologic malignancies.Authorship 585932Authorship 5950810Authorship 600987Authorship 56138316371132Kimata Y, Ishiwata-Kimata Y, Yamada S, Kohno KGenes to cells : devoted to molecular & cellular mechanismsYeast unfolded protein response pathway regulates expression of genes for anti-oxidative stress and for cell surface proteins. Genes Cells. 2006 Jan; 11(1):59-69.Genes Cells2006-01-01T00:00:002006Yeast unfolded protein response pathway regulates expression of genes for anti-oxidative stress and for cell surface proteins.20478417Suzuki H, Yamada S, Toyama Y, Takeda SBiochimica et biophysica actaThe C-terminal domain is sufficient for host-binding activity of the Mu phage tail-spike protein. Biochim Biophys Acta. 2010 Sep; 1804(9):1738-42.Biochim Biophys Acta2010-05-15T00:00:002010The C-terminal domain is sufficient for host-binding activity of the Mu phage tail-spike protein.22806897Song S, Rudra S, Hasselle MD, Dorn PL, Mell LK, Mundt AJ, Yamada SD, Lee NK, Hasan YCancerThe effect of treatment time in locally advanced cervical cancer in the era of concurrent chemoradiotherapy. Cancer. 2013 Jan 15; 119(2):325-31.Cancer2012-07-17T00:00:002012The effect of treatment time in locally advanced cervical cancer in the era of concurrent chemoradiotherapy.Authorship 96018225541622West AH, Yamada SD, MacMahon H, Acharya SS, Ali SM, He J, Lukas RV, Miller VA, Salgia RCase reports in clinical pathologyUnique metastases of ALK mutated lung cancer activated to the adnexa of the uterus. Case Rep Clin Pathol. 2014 Sep; 1(2):151-154.Case Rep Clin Pathol2014-09-01T00:00:002014Unique metastases of ALK mutated lung cancer activated to the adnexa of the uterus.Authorship 967571127856443Eckert MA, Pan S, Hernandez KM, Loth RM, Andrade J, Volchenboum SL, Faber P, Montag A, Lastra R, Peter ME, Yamada SD, Lengyel ECancer discoveryGenomics of Ovarian Cancer Progression Reveals Diverse Metastatic Trajectories Including Intraepithelial Metastasis to the Fallopian Tube. Cancer Discov. 2016 12; 6(12):1342-1351.Cancer Discov2016-10-07T00:00:002016Genomics of Ovarian Cancer Progression Reveals Diverse Metastatic Trajectories Including Intraepithelial Metastasis to the Fallopian Tube.